Genetics Institute, Inc.

Other

Michael R Bowman

John M McCoy

Kenneth A Jacobs

Edward R LaVallie

Lisa A Racie

David Merberg

Maurice Treacy

Vikki A Spaulding

Cheryl Evans

Polynucleotides encoding novel proteases designated 'FMH-1' are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

ICE/CED-3 like protease designated FMH-1

Polynucleotides encoding novel proteases designated &ldquo;FMH-1&rdquo; are disclosed. Host cells transformed with such polynucleotides and methods for making FMH-1 proteases are also disclosed. The invention also provides FMH-1 proteases and antibodies that react with them, along with pharmaceutical compositions comprising FMH-1 proteases or polynucleotides encoding FMH-1 proteases. Methods for treating conditions associated with excessive or insufficient apoptosis by administering such pharmaceutical compositions are also disclosed.

Novel polynucleotides and the proteins encoded thereby are disclosed.

Secreted proteins and polynucleotides encoding them

A novel secreted protein, BA3.1, is disclosed. Polynucleotides encoding BA3.1 are also provided.

Secreted protein, BA3.1, and polynucleotides encoding same

Polynucleotides encoding retenoid receptor-1 (RR1) are disclosed. RR1 proteins and methods for their production, ligands for the RR1 and methods for their identification, and inhibitors of binding of RR1 and its ligands and methods for their identification are also disclosed.

Growing community of inventors

Canton, MA, United States of America

Michael R Bowman